President Trump And Drug Pricing: Rhetorical Improvement But Uncertainty Remains
Executive Summary
In his first address to Congress, President Trump didn’t drop drug pricing as a theme, but he also didn’t accuse the industry of 'getting away with murder.' For innovators, that’s at least a rhetorical improvement. Now the debate becomes what the US president means by prices that are 'artificially' high.
You may also be interested in...
Who Speaks For The White House On Drug Prices? Industry Better Hope It Is Not Donald Trump
The disconnect between what Donald Trump says about drug pricing in unscripted settings and what the Administration says in more formal, policy-articulating contexts is very stark. For biopharma companies, the 'official' statements are reassuring – but it would be dangerous to discount Trump’s populist instincts altogether.
Trump Slams FDA Regulations In Joint Session Of Congress
US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.
Carrots and Stick: Biopharma At The White House
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.